Author

Karel Petrak

NangioTx Inc. - Cited by 2,117 - target-specific drug delivery

Biography

Karel Petrak is currently residing at NangioTx Inc., 220 W 98th, Apt 10N, New York, NY 10025, USA. Karel Petrak had published numerous research papers and articles in reputed journals and has various other achievements in the related studies.An executive with 40 years experience in pharmaceutical industry, with a demonstrated success in pharmaceutical and biotechnology drug development, drug discovery and delivery of conventional drugs, proteins, and peptides, now seeking to apply industrial experience in basic and translational academic research. Has established a solid record of the NIH SBIR funding
Title
Cited by
Year
Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes
BD Freimark, HP Blezinger, VJ Florack, JL Nordstrom, SD Long, ...The Journal of Immunology 160 (9), 4580-4586, 1998199
220
1998
Essential properties of drug-targeting delivery systems
K PetrakDrug discovery today 10 (23-24), 1667-1673, 2005200
171
2005
Oral Lactoferrin Results in T Cell–Dependent Tumor Inhibition of Head and Neck Squamous Cell Carcinoma In vivo
JS Wolf, G Li, A Varadhachary, K Petrak, M Schneyer, D Li, ...Clinical Cancer Research 13 (5), 1601-1610, 2007200
138
2007
Randomized controlled trial of talactoferrin oral solution in preterm infants
MP Sherman, DH Adamkin, V Niklas, P Radmacher, J Sherman, ...The Journal of pediatrics 175, 68-73. e3, 2016201
54
2016
Ultrasonic nebulization of cationic lipid-based gene delivery systems for airway administration
R Pillai, K Petrak, P Blezinger, D Deshpande, V Florack, B Freimark, ...Pharmaceutical research 15, 1743-1747, 1998199
39
1998
Nanotechnology and site-targeted drug delivery
K PetrakJournal of Biomaterials Science, Polymer Edition 17 (11), 1209-1219, 2006200
34
2006
Lactoferrin-enhanced anoikis: a defense against neonatal necrotizing enterocolitis
MP Sherman, K PetrakMedical hypotheses 65 (3), 478-482, 2005200
30
2005
Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
A Varadhachary, R Barsky, F Pericle, K Petrak, Y WangUS Patent 7,901,879, 2011201
23
2011
Composition of lactoferrin related peptides and uses thereof
A Varadhachary, P Glynn, K Petrak, J EngelmayerUS Patent 7,420,033, 2008200
22
2008
Composition of lactoferrin related peptides and uses thereof
A Varadhachary, P Glynn, K Petrak, J EngelmayerUS Patent 7,3,381, 2007200
18
2007
Lactoferrin in the reduction of pain
A Varadhachary, K PetrakUS Patent 7,323,443, 2008200
13
2008
Oral lactoferrin in the treatment of sepsis
A Varadhachary, K PetrakUS Patent App. 10/728,521, 2004200
12
2004
Challenges in translating from bench to bed-side: pro-angiogenic peptides for ischemia treatment
K Petrak, R Vissapragada, S Shi, Z Siddiqui, KK Kim, B Sarkar, VA KumarMolecules 24 (7), 1219, 2019201
11
2019
Formulations for electroporation
F MacLaughlin, S Li, Y Li, K PetrakUS Patent App. 09/322,602, 2002200
10
2002
Targeted Drug Delivery––Quo Vadis?
K PetrakDrug Development Research 73 (2), 5-65, 2012201
9
2012
Intracellular Delivery III
A Prokop, V Weissig, A ProkopSpringer, 2016201
8
2016
Targeting drug-delivery systems: promises, promises, and more promises. Let’s change the paradigm
K Petrak, V HasirciRecent Advances in Drug Delivery Research (Editor Valerio Voliani), 16-180, 2013201
7
2013
Formulations for electroporation
F MacLaughlin, S Li, Y Li, K PetrakUS Patent App. 09/903,009, 2002200
7
2002
Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
A Varadhachary, R Barsky, F Pericle, K Petrak, Y WangUS Patent App. 13/54,208, 2012201
6
2012
Precision medicine and site-specific drug delivery
K PetrakAdvances in Cancer Research 3, 1-4, 2015201
6
2015

Referred From: https://scholar.google.com/citations?user=xY9C9XUAAAAJ&hl=en

Cited by
Citations 2117
h-index 21
i10-index 41
Recommended Journals
Open Access Journals